An observational study in Peri-Implantitis, Sinusitis and Sinusitis, Acute, sponsored by Universitat Internacional de Catalunya. Recruiting at 2 sites in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-06-29.
Sponsored by Universitat Internacional de Catalunya · Observational
Scientific evidence regarding the influence of peri-implantitis on Schneider's membrane thickening is scarce and limited. Similarly, to date, there is no literature documenting the resolution of implant-associated maxillary sinusitis with peri-implantitis after treatment of peri-implantitis or removal of the implant. Therefore, the aim of this case-control study is to investigate the association between peri-implantitis and maxillary sinusitis. On the other hand, the changes that occur at the level of the maxillary sinus membrane after treatment of peri-implantitis or after implant explantation will be evaluated.
Background Scientific evidence regarding the influence of peri-implantitis on Schneider's membrane thickening is scarce and limited. Similarly, to date, there is no literature documenting the resolution of implant-associated maxillary sinusitis with peri-implantitis after treatment of peri-implantitis or removal of the implant.
Objectives Therefore, the aim of this case-control study is to investigate the association between peri-implantitis and maxillary sinusitis. On the other hand, the changes that occur at the level of the maxillary sinus membrane after treatment of peri-implantitis or after implant explantation will be evaluated.
Hypothesis H01: The presence of implants placed in the posterior maxillary region affected by peri-implantits is associated with sinus membrane thickening or maxillary sinusitis.
H11: The presence of implants placed in the posterior maxillary region affected by peri-implantits is not associated with sinus membrane thickening or maxillary sinusitis.
H02: Treatment of peri-implantitis in implants placed in the posterior maxillary region can resolve maxillary sinusitis or reduce sinus membrane thickening.
H12: Treatment of peri-implantitis on implants placed in the posterior maxillary region cannot resolve maxillary sinusitis or reduce sinus membrane thickening.
Material and methods Study design The study will present a case-control design. Patients will be retrospectively recruited from a private clinic exclusively dedicated to periodontics and implantology (Clínica CICOM, Badajoz, Spain).
Study setting The study will be conducted in a private practice associated with the Universitat Internacional de Catalunya (UIC). The study protocol and informed consent will be reviewed by the Ethics Committee of the Universitat Internacional de Catalunya (UIC, Barcelona, Spain) and the Declaration of Helsinki, 1975, revised in 2013, will be followed.
Study population All patients included in the study will sign the corresponding informed consent forms for each of the treatments received, as well as for the use of their demographic and radiographic data for scientific purposes.
The subjects recruited will be edentulous (partial/total) patients who previously had implants placed in the posterior region of the maxilla for oral rehabilitation. The case group will consist of 20 patients who will have implants diagnosed with peri-implantitis while in the control group the 20 subjects included will have implants with peri-implant health.
Demographic data
A set of demographic data shall be obtained and recorded:
Implant-related variables:
Implant macro-design (transmucosal or bone level)
Radiographic analysis Images of the included patients will be obtained with the CBCT-ICAT Model 17-19 (Imaging Sciences International LLC, Hatfield, PA, USA). The parameters were set as 16x13 mm in width and depth, 120 kVp, 20.27 mAs, scan time 14.7 seconds, resolution at 0.25 voxels and field of view varying according to the region scanned. Radiographic evaluation will include analysis of implants, adjacent teeth and maxillary sinuses/sinus membranes.
Radiographic analysis of the implants
A pre-calibrated examiner (RP) will analyze each of the implants included in the study using the coDiagnostiX software (Implant planning Software, Dental Wings GmbH, Chemnitz, Germany). The following parameters will be evaluated:
These radiographic measurements shall be repeated again in the case group subjects after the peri-implantitis has been treated. The time between treatment and the re-evaluation tac shall be at least 6 months.
Radiographic evaluation of adjacent teeth A pre-calibrated examiner (RP) will analyze each adjacent tooth for the presence of periapical lesions or carious lesions using the coDiagnostiX software (Implant planning Software, Dental Wings GmbH, Chemnitz, Germany). This is recorded as presence or absence.
Radiographic evaluation of the maxillary sinus
A pre-calibrated examiner (BA) will analyze each maxillary sinus using Dolphin 3D Images software. The following parameters will be evaluated:
These radiographic measurements will be repeated again in the case group subjects after treatment of peri-implantitis or after explantation of implants in more advanced cases. The time between treatment and the re-evaluation tac will be at least 6 months.
In addition, the following information shall be obtained for each maxillary sinus and sinus membrane:
Case definition of peri-implantitis Peri-implantitis will be defined according to the 2017 Word Workshop of Periodontal and Peri-implant diseases. Therefore, the case definition applied will be as follows: presence of bleeding and/or oozing on soft probing (∼0.2N), peri-implant probing depths of ≥6 mm, bone levels ≥3 mm apical to the most coronal portion of the intra-osseous part of the implant according to periapical radiography.
Morphology and severity of peri-implant bone defect The characterization of peri-implant defects will be based on the morphology of the defect (Classes I-III) and severity (grades L-M-A), as previously proposed. Briefly, according to morphology it will be classified as follows Class I: infra-bony defect (Class IA: buccal dehiscence, Class IB: 2- to 3-wall defect), Class II: supra-crestal/horizontal defect, and Class III: combined defect (Class IIIA: buccal dehiscence + horizontal bone loss, Class IIIB: 2- to 3-wall defect + horizontal bone loss, Class IIIC: circumferential defect + horizontal bone loss). In terms of severity, implants shall be classified as follows: Mild (L): 3 to 4 mm/ \<25% of implant length, Moderate (M): 4 to 5 mm/≥25% to 50% of implant length, and Advanced(A): >6 mm/ >50% of implant length.
Statistical analysis The statistical package (SPSS 15.0, SPSS Inc., Chicago, IL, USA, STATISTICS, version 7.1StatSoft, Inc., USA AND R 2.14.0) will be used to analyze the data. Pearson's correlation test will be applied for the assessment of confounding factors.
322 studies on the registry are indexed under Peri-Implantitis; 88 are open to participants now.
This study's planned enrollment of 40 is below the median of 83 across 121 observational studies indexed under Peri-Implantitis.
Browse Peri-Implantitis studies →Universitat Internacional de Catalunya is the lead sponsor of 151 studies on the registry; 46 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients included in the study signed the corresponding informed consent forms for each of the treatments received, as well as for the use of their demographic and radiographic data for scientific purposes.
The subjects recruited will be edentulous (partial/total) patients who previously had implants placed in the posterior region of the maxilla for oral rehabilitation. The case group will consist of 20 patients who will have implants diagnosed with peri-implantitis while in the control group the 20 subjects included will have implants with peri-implant health.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The case group will consist of 20 patients who will have implants diagnosed with peri-implantitis, according to the 2017 World Workshop Classification case definition.
Other: Retrospective analysis of demographic and radiographic data previously obtained from the patient.
The control group will include 20 subjects who will have implants with peri-implant health according to the 2017 World Workshop Classification case definition.
Other: Retrospective analysis of demographic and radiographic data previously obtained from the patient.
The patient's demographic data obtained previously by anamnesis and clinical examination will be retrospectively analyzsed. On the other hand, a radiographic evaluation including analysis of the implants, adjacent teeth and maxillary sinuses/sinus membranes shall be performed using computer software.
Sinus membrane thickening changes after peri-implantitis treatment
Sagital and coronal linear measurements of membrane thickening
Time frame: 6 months
Severity of peri-implantitis in implants with maxillary sinusitis
Linear measurements at 4 implant sites measured on the available CT scans of the patients
Time frame: 1 month
Volume dimensional changes of the sinus membrane
Total membrane occupancy inside the sinus and amount of sinus free of occupation
Time frame: 1 month
Plan to share: No — Data collected from patients may only be processed by the research team of this study and will not be shared with other researchers.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitat Internacional de Catalunya →